{
    "2020-08-26": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Could This Options Trade In AbbVie Generate A 93% Return By September?",
                "features": {
                    "keywords": [
                        "options trade",
                        "AbbVie",
                        "93% return"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "FDA approval",
                        "Rinvoq",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Hedge Funds Have Never Been This Bullish On AbbVie (ABBV)",
                "features": {
                    "keywords": [
                        "hedge funds",
                        "bullish",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie vs Biogen: Which Drugmaker Scores A ‘Strong Buy’ Street Consensus?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Biogen",
                        "strong buy",
                        "street consensus"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}